News / AI & Data
Microsoft Research Unveils Quine, an AI System to Revolutionize Biological Research Published on 29 September 2026 by Christ-loisele (3 min read)
Microsoft Research has unveiled Quine, a multimodal AI model designed to model biology at various scales. Developed in collaboration with Harvard’s and MIT’s Broad Institute, this system accelerates the discovery of therapeutic compounds and optimizes research cycles in oncology.
Video: Microsoft Research Forum | Season 2, Episode 1 (Microsoft Research, YouTube) A Multimodal Model to Integrate Biological Complexity
Quine is an AI system designed to create a global multimodal model of biology, according to Microsoft Research. Unlike traditional tools, it combines genomic, proteomic, chemical, RNA, cellular state, and bioimaging data to reason across different biological scales. The system was trained on diverse datasets to enhance performance rather than dilute it, as Microsoft explains.
Developed in collaboration with the Harvard and MIT Broad Institute , Quine connects models, scientific tools, literature, and researchers through an interactive interface. It aims to accelerate the iterative process of science by proposing hypotheses, suggesting experiments, and validating obtained results.
The Quine system does not need to be perfect; it simply must usefully guide experiment design.
Image: Introducing Quine: An AI Research System Designed for the Complexity of Biology (Microsoft Research, official image) Concrete Results in Oncology and Experimental Validation
Quine has already demonstrated its utility in oncology, particularly in the study of pancreatic ductal adenocarcinoma (PDAC) , the most common and one of the most difficult-to-treat forms of pancreatic cancer, according to Microsoft. The system helped prioritize compounds predicted to induce therapeutic changes in tumor states. Several top-ranked candidates were validated through lab tests, confirming a Quine prediction: some compounds drive cells toward a distinct third phenotype, beyond the classic basal axis.
Microsoft emphasizes that the compound selection process, which would normally take months, was completed over a weekend, saving research time and costs. These results provide early evidence that AI can uncover opportunities for drug repurposing and discovery.
An Experimental Tool for Research, with an Expanded Access Program
Quine remains an experimental technology, not intended for clinical or medical use, as Microsoft Research specifies. Its outputs may be incomplete or inaccurate and require rigorous scientific validation. The system is currently accessible via the Quine Fellows program , which provides privileged access to a restricted group of scientists to accelerate their research.
Microsoft Research has been working for over two decades at the intersection of computation and biology, covering fields such as immunology, virology, genomics, and protein engineering. In the long term, access to Quine could expand through products like Microsoft Discovery , once the technology matures.
What this changes here
For businesses and government agencies in Benin and West Africa, the emergence of Quine could open opportunities in biomedical and pharmaceutical research. Local laboratories specializing in genomics, virology, or oncology could benefit from similar tools to accelerate their discoveries, particularly in combating endemic diseases like malaria or viral infections.
Public institutions, such as research centers or health ministries, could be interested in international collaborations to integrate advanced AI models into their research protocols. However, as access to Quine remains limited and experimental, a gradual adaptation to emerging technologies will be necessary to avoid pitfalls linked to premature use.
Sources 
